Nitasha Sarswat to Prealbumin
This is a "connection" page, showing publications Nitasha Sarswat has written about Prealbumin.
Connection Strength
1.817
-
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial. J Am Heart Assoc. 2026 Oct 06; 15(19):e050566.
Score: 0.241
-
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
Score: 0.235
-
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation. 2026 Jan 27; 153(4):214-225.
Score: 0.228
-
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1911-1923.
Score: 0.221
-
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 10 26; 389(17):1553-1565.
Score: 0.198
-
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis. 2021 10 03; 16(1):411.
Score: 0.172
-
An Orphan Disease No More: Additional Treatment Options for Cardiac Amyloidosis. J Card Fail. 2020 09; 26(9):760-761.
Score: 0.159
-
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026 05 01; 11(5):446-454.
Score: 0.059
-
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. JAMA Cardiol. 2026 01 01; 11(1):57-67.
Score: 0.058
-
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging. 2025 Aug; 41(8):1487-1496.
Score: 0.055
-
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 04; 151(9):601-611.
Score: 0.053
-
Non-invasive diagnosis of transthyretin cardiac amyloidosis utilizing typical late gadolinium enhancement pattern on cardiac magnetic resonance and light chains. Eur Heart J Cardiovasc Imaging. 2023 05 31; 24(6):829-837.
Score: 0.048
-
99m Technetium-pyrophosphate bone scan: A potential biomarker for the burden of transthyretin amyloidosis in skeletal muscle: A preliminary study. Muscle Nerve. 2023 Feb; 67(2):111-116.
Score: 0.046
-
Progressive Multiple Mononeuropathy in a Patient With Familial Transthyretin Amyloidosis After Liver Transplantation. J Clin Neuromuscul Dis. 2022 Mar 01; 23(3):143-147.
Score: 0.044